Recent studies on the pathophysiological mechanisms of CXCL12/CXCR4 axis in the pathogenesis of pain by various nerve injury and neuropathy models, including diabetic neuropathy, demonstrate the axis as a promising pharmacological target. This evidence concerns the gene CXCL12 and neuropathy.